Previous 10 | Next 10 |
Natera (NTRA): Q1 GAAP EPS of -$0.74 beats by $0.28.Revenue of $152.3M (+62.0% Y/Y) beats by $37.88M.Press Release For further details see: Natera EPS beats by $0.28, beats on revenue
Natera Reports First Quarter 2021 Financial Results PR Newswire AUSTIN, Texas , May 6, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the first quarter ended ...
Natera to Present New Colorectal Cancer and Multiple Myeloma Data at the 2021 Annual ASCO Meeting ASCO presentations come on the heels of new Signatera™ data in ovarian cancer presented at AACR PR Newswire AUSTIN, Texas , May 3, 2021 /PRNewswire/ -...
Natera Announces First Quarter 2021 Earnings Conference Call PR Newswire AUSTIN, Texas , April 29, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its...
A local coverage determination ("LCD") published today by the Centers for Medicare and Medicaid Services ("CMS") and effective June 6 will provide a pathway to cover management of patients with organ transplants, benefitting Natera (NTRA), according to SVB Leerink.Analyst Puneet Souda writes ...
Prospera™ Transplant Assessment Test: Path Established to Expand Future Coverage to Multiple Organs Medicare issues new coverage guidance for dd-cfDNA testing, enabling coverage beyond kidney transplants PR Newswire AUSTIN, Texas , April 22, 2021 /PRNe...
Natera Implements First Wave of Panorama® AI Improvements With Immediate Impact on Patient Experience and COGS PR Newswire AUSTIN, Texas , April 7, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, ha...
The challenge by the U.S. Federal Trade Commission to block the proposed acquisition of Grail by Illumina ([[ILMN]] +4.0%) led to a ~6.6% sell-off of the stock yesterday.Citing a brighter post-COVID future for the company, Canaccord Genuity has upgraded the stock to buy from hold with the pri...
Natera (NTRA) and Tesis Labs, a US multi-region lab services provider with labs in Colorado, Texas and Arizona, announce a strategic partnership in the field of prenatal genetic testing.The collaboration will allow Tesis to broaden its portfolio of genetic testing offering...
Natera and Tesis Labs Announce Strategic Collaboration on Prenatal Genetic Testing PR Newswire AUSTIN, Texas , March 31, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in non-invasive genetic testing and analysis of cfDNA, a...
News, Short Squeeze, Breakout and More Instantly...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-13 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...